Document:

exv10w28

 

EXHIBIT 10.28

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

January 11, 2008

Three Rivers Pharmaceuticals, LLC

301 Commerce Park Drive

Cranberry Township, PA 16066

Ladies and Gentlemen:

Reference is made to the Asset Purchase Agreement (the “Agreement”) dated as of December 19, 2007
by and between Valeant Pharmaceuticals North America (“Seller”) and Three Rivers Pharmaceuticals,
LLC (“Buyer”). Capitalized terms used herein without definition shall have the meaning ascribed to
them in the Agreement.

	1.	 	Allocation Schedule. Notwithstanding any provision of Section 1.7 of the Agreement,
Buyer and Seller agree that Buyer shall prepare and deliver to Seller the Allocation as
promptly as practicable but in no event later than the day that [...***...] after the Closing
Date. The Allocation shall become final and binding on the parties, unless Seller notifies
Buyer within fifteen (15) days after receipt of such Allocation of Seller’s disagreement with
such Allocation. In the event Seller timely notifies Buyer of such disagreement, the parties
shall resolve such disagreement in the manner described in Section 9.3 of the Agreement. All
provisions of Section 1.7 of the Agreement shall remain in full force and effect as modified
hereby.

	2.	 	Additional Assumed Contracts. The parties agree that [...***...], shall be deemed to be set forth in
Section 1.1(a)(iv) of the Seller Disclosure Letter. The parties further agree that [...***...], shall be deemed to be set forth in Section
1.1(a)(iv) of the Seller Disclosure Letter.

	3.	 	Reference to Exhibits in the Agreement. The parties agree that each of the Bill of
Sale, the General Assignment, the Patent Assignment, the Trademark Assignment and the
non-foreign person certificate referenced in Section 2.2(e) of the Agreement to be delivered
at Closing pursuant to Sections 2.2 and 2.3 of the Agreement shall be substantially in the
forms attached to the Agreement as Exhibit B, Exhibit C, Exhibit D, Exhibit E and
Exhibit F, respectively. The parties acknowledge that the foregoing exhibits are incorrectly
referenced in Section 2.2 of the Agreement as Exhibit C, Exhibit D, Exhibit E, Exhibit F and
Exhibit G, respectively.

	4.	 	Section 5.10(b)(i)(A) and Section 5.10(b)(i)(B) of the Seller Disclosure Letter.
Attached as Annex 1 and Annex 2 hereto are Section 5.10(b)(i)(A) and Section
5.10(b)(i)(B) of the Seller Disclosure Letter updated as of the close of business on
January 11, 2008. The

***Confidential
Treatment Requested

1.

 

	 	 	parties agree that Seller shall not be required to update Section
5.10(b)(i)(A) and Section 5.10(b)(i)(B) of the Seller Disclosure Letter for any
event or change occurring after January 11, 2008.

	5.	 	Miscellaneous.

     (a) Seller and Buyer hereby acknowledge and agree that this letter agreement constitutes an
amendment to the Agreement in accordance with Section 9.5 of the Agreement.

     (b) Each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or
words of like import referring to the Agreement shall mean and be a reference to the Agreement as
amended by this letter agreement.

     (c) Each reference to the Agreement in the Ancillary Agreements and any other ancillary
agreement entered into pursuant to or in connection with the Agreement shall mean and refer to the
Agreement as amended by this letter agreement.

     (d) This letter agreement shall be governed by and construed in accordance with the laws of
the State of New York without regard to its conflicts of laws principles that would mandate the
application of the laws of another jurisdiction.

     (e) This letter may be executed in two or more counterparts, each of which shall be deemed to
be an original, but all of which shall constitute one and the same agreement. Each of the parties
agrees to accept and be bound by facsimile or PDF signatures hereto.

     (f) Any dispute, controversy or claim arising under, out of or in connection with this letter
agreement or the breach, termination or validity thereof shall be referred to and finally settled
by arbitration in accordance with the terms of Section 9.3 of the Agreement.

[Remainder of page intentionally left blank.]

2.

 

     If the agreements and understandings contained in this letter agreement are acceptable to
Buyer, please indicate such approval by signing this letter in the space indicated below and return
a fully executed copy of this letter to Seller.

	 	 	 	 	 
	 	Sincerely,

Valeant Pharmaceuticals North America

 	 
	 	By:  	
/s/Timothy C. Tyson	 
	 	 	Name:  	Timothy
C. Tyson	 
	 	 	Title:  	President
and CEO	 
	 

	 	 	 	 	 
	Accepted and Agreed

Three Rivers Pharmaceuticals, LLC

 	 	 
	By:  	
/s/Donald J. Kerrish	 	 
	 	Name:  	Donald
J. Kerrish	 	 
	 	Title:  	President and CEO	 	 

3.

 

	 	 	 	 	 

Annex 1

Section 5.10(b)(i)(A)

For [...***...] following the Closing, Seller shall be financially and legally
responsible for all Liabilities associated with any Product Returns for any Infergen sold by Seller
prior to the Closing Date.

***Confidential
Treatment Requested

4.

 

Annex 2

Section 5.10(b)(i)(B)

Each of Buyer and Seller shall be financially and legally liable for Product Returns out of the
Lots set forth below to the extent of Products sold out of these Lots by it.

LOT

NUMBER

[...***...]

[...***...]

[...***...]

***Confidential
Treatment Requested

5.exv10w32

 

EXHIBIT 10.32

SEPARATION AND RELEASE AGREEMENT

Recitals

     A. Wesley P. Wheeler (“Wheeler”) was employed as President, North America, R& D, and Global
Manufacturing of Valeant Pharmaceuticals North America (“VPNA”), a subsidiary of Valeant
Pharmaceuticals International (collectively, the “Company”).

     B. Wheeler resigned from the Company effective December 7, 2007 (the “Termination Date”) and
has agreed to release the Company as provided herein in exchange for the consideration described in
the attached Exhibit A (the “Separation Payment”). Company has agreed that, in return for Wheeler
signing this Separation and Release Agreement (“Agreement”), the Company will pay him the
Separation Payment. Wheeler understands that, regardless of whether he signs this Agreement, the
Company will pay his any accrued salary, vacation and other benefits to which he is entitled and
that he will be able to exercise his post termination rights with respect to vested stock options
and other forms of equity in accordance with the applicable plans and grant agreements. Wheeler
also agrees that communication and interactions he has with the Company and external parties will
be positive in nature and will in no way defame the Company or its management. In consideration
for the Separation Payment he is receiving under this Agreement:

     1. Release. Wheeler hereby releases the Company and its parent, subsidiaries, predecessors,
successors, and affiliates, and their respective directors, officers, employees, shareholders, and
agents and all Company-sponsored benefit plans, plan fiduciaries, plan administrators and plan
service providers (collectively, the “Releasees”) from any and all claims, demands, causes of
action, liabilities, damages and obligations of every kind, whether known or unknown, arising at
any time prior to and through the date Wheeler signs this Agreement. This general release
includes, but is not limited to: all federal and state statutory and common law claims; claims
related to his employment or termination of his employment, claims arising under theories of
contract, tort, discrimination, harassment, retaliation, fraud, emotional distress theories,
including all claims for compensation or benefits (including all bonus programs of any kind);
claims for any form of equity; claims for breach of employee handbooks or policies, breach of
statutory or ethical duties, breach of the covenant of good faith and fair dealing, promissory
estoppel, fraud, breach of any implied covenants, defamation (including but not limited to slander
and libel), invasion of privacy, intentional infliction of emotional distress, negligence
(including but not limited to negligent retention, negligent supervision, gross negligence, and the
negligent infliction of emotional distress) as well as any other tort claim; and releasable claims
related to leaves of absences. In releasing claims unknown to him at present, Wheeler acknowledges
that Wheeler has

1.

 

understood and waived all rights and benefits under Section 1542 of the California
Civil Code, and any law or legal principle of similar effect in any jurisdiction:

“A general release does not extend to claims which the creditor does not know or suspect to
exist In his favor at the time of executing the release, which if known by him must have
materially affected his settlement with the debtor.”

     Wheeler acknowledges that he is knowingly and voluntarily waiving and releasing any rights
that he may have under the Age Discrimination in Employment Act of 1967, as amended (“ADEA”), and
that the consideration given for the waiver and release in the preceding paragraph is in addition
to anything of value to which he was already entitled, such as the proceeds of his 401(k) account
or the right to exercise, according to the provisions of the applicable stock option grants and
agreements, any stock options or other equity vested as of the termination date.

     The Company specifically releases, waives, and forever discharges Wheeler, his successors in
interest, past, present and future assigns, from any and all past claims, demands, actions,
liabilities and causes of actions, of every kind and character, whether asserted or unasserted,
whether known or unknown, suspected or unsuspected, in law or in equity, for or by reason of any
matter, cause or thing whatsoever, arising out of Wheeler’s personal actions during his tenure as
an employee and officer of the Company so long as such personal actions were not of an illegal
nature. As such, except for the enforcement of this Agreement or any rights preserved under this
Agreement, the Company hereby covenants that they will not, based on any of Wheeler’s personal
actions during his tenure with the Company, sue or bring any claim or action against Wheeler. This
Covenant Not to Sue shall be a complete defense to any such claim or suit by the Company.

     In addition, as it relates to actions concerning Wheeler’s actions as an officer of the
Company, the Company acknowledges that Wheeler is covered by the Company’s Director and Officer
Liability insurance policy in place during his tenure.

     2. Exceptions. Notwithstanding anything herein to the contrary, Wheeler is not releasing: (a)
any claims that relate to his right to enforce this Agreement, (b) his rights of indemnification
and directors and officers liability insurance coverage (or replacements therefore) to which he was
entitled immediately prior to the date of this Agreement with regard to his service on behalf of
the Company and its affiliates; (c) his rights under any tax-qualified pension or claims for
accrued vested benefits under any other employee benefit plan maintained by the Company; or (d) his
rights as a stockholder. He further understands that nothing in this Agreement shall be construed
to prohibit him from filing a charge or complaint with the Equal Employment Opportunity Commission
or with any

2.

 

state agency responsible to enforce laws prohibiting discrimination in employment,
including a challenge to the validity of this Agreement under the ADEA or the Older Workers Benefit
Protection Act, and nothing in this Agreement prevents him from participating in any investigation
or proceeding conducted by the Equal Employment Opportunity Commission or any such state agency.
Wheeler further understands and agrees that if he, or someone acting on his behalf, files, or
causes to be filed, any such claim, charge, complaint, or action against the Releasees, he
expressly waives any right to recover any damages or other relief, whatsoever, from the Releasees,
including costs and attorneys’ fees.

     Wheeler further acknowledges that he has been advised by this writing that: (a) his waiver and
release does not apply to any rights or claims that may arise after the execution date of this
Agreement; (b) he has the right to consult with an attorney prior to executing this Agreement; (c)
he has twenty-one (21) days from the date this agreement is submitted to him to consider this
Agreement (although he may choose voluntarily to execute this Agreement earlier);

(d) he has seven (7) days following the execution of this Agreement to revoke the Agreement by
providing written notice to the Timothy C. Tyson, President and Chief Executive Officer; and (e)
this Agreement will not be effective until the date upon which the revocation period has expired,
which will be the eighth day after this Agreement is executed by him (“the Effective Date”).

     3. No Other Payments. Wheeler acknowledges and agrees that, other than what is provided for
herein, he is not eligible or entitled to receive, pursuant to any policy, prior contracts, plans,
agreements or otherwise, any other payment, benefit or consideration in connection with his
employment or the termination of his employment with the Releasees including, without limitation,
any payments or benefits under any severance policy, plan or contract.

     4. Defense of Litigation. Wheeler agrees to cooperate with Valeant in connection with the
defense of all outstanding litigation with respect to which Wheeler has relevant information. Such
cooperation shall include, but is not limited to: (a) voluntarily appearing at the request of
Valeant for depositions at the times and places reasonably agreed upon by Valeant and Wheeler; (b)
appearing at trial or any hearing for the purpose of testifying or otherwise providing evidence in
the cases. To the extent that Wheeler suffers any loss in income (including use of vacation pay
from a subsequent employer), Valeant will reimburse him for the amount of the loss, as well as any
out of pocket expenses for travel etc.

     5. Proprietary Information. Wheeler will immediately return all Company property and
documents and any other embodiments of the Company’s proprietary or confidential information (and
all reproductions thereof, in whole or in part) in his possession or control. Wheeler will not use
or disclose the Company’s confidential or proprietary information. Wheeler will comply with any

3.

 

other obligations regarding protection of the Company’s proprietary and confidential information,
assignment and disclosure of inventions, and return of property which Wheeler may have undertaken
previously in agreements Wheeler has signed with the Company.

     6. Enforcement of Proprietary Rights. Wheeler will assist the Company in every proper way to
obtain, and from time to time enforce, United States and foreign rights in trade secrets, patents,
copyrights, and other intellectual property rights (“Proprietary Rights”) relating to inventions,
ideas, processes, formulas, source and object codes, data, programs and other works of authorship,
know-how, improvements, discoveries, developments, designs, and techniques in any and all
countries. To that end, Wheeler will execute, verify and deliver such documents and perform such
other acts (including appearances as a witness) as the Company may reasonably request for use in
applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights
and the assignment thereof. In addition, Wheeler will execute, verify and deliver assignments of
such Proprietary Rights to the Company or its designee. The Company shall compensate Wheeler at a
reasonable rate after his termination for the time actually spent by him at the Company’s request
on such assistance.

     In the event the Company is unable for any reason, after reasonable effort, to secure his
signature on any document needed in connection with the actions specified in the preceding
paragraph, Wheeler hereby irrevocably designates and appoint the Company and its duly authorized officers and agents as his agent and attorney in fact, which appointment is coupled with an interest, to act for and in his behalf to execute, verify and file any such documents
and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with
the same legal force and effect as if executed by him. Provided, however, that Wheeler’s
designation of the Company as his agent and attorney in fact, as granted in this paragraph, is for
a period of 6 months from the execution of this Agreement. Wheeler agrees to extend this term if
reasonably necessary for another 6 month term. Reasonable efforts by the Company to contact
Wheeler includes, but are not limited to, contact at his last known home and business address and
phone number and through his designated agent, Alexander E. Kahn of Moore Colson at 678-385-6050.
Wheeler agrees to notify the Company of changes to his contact information as soon as practicable
during the term of this Agreement.

     7. Governing Law and Jurisdiction. This Agreement will be governed by and construed and
enforced in accordance with the laws of the State of California without giving effect to the
conflict of law principles thereof. The Company and Wheeler agree to resolve any claims they may
have in regards to this Agreement, and the execution and enforcement thereof, in, and irrevocably
consent to the exclusive jurisdiction of, the state and federal courts sitting in Orange County,
California.

4.

 

     8. Nonadmission of Liability. This Agreement is not an admission of wrongdoing by any
released party. Wheeler agrees that he has not suffered any discrimination on account of his age,
sex, race, national origin, marital status, sexual orientation, or any other protected status, and
none of these ever has been an adverse factor used against him by any released party. Wheeler has
not suffered any job related wrongs or injuries for which Wheeler might still be entitled to
compensation or relief, such as an injury for which Wheeler might receive a workers’ compensation
award in the future.

     9. Severability. Should any of the provision in this Agreement be declared or be determined
to be illegal or invalid, all remaining parts, terms or provisions shall be valid, and the illegal
or invalid part, term, or provision shall be deemed not to be a part of this Agreement.

     TAKE THIS RELEASE HOME, READ IT, AND CAREFULLY CONSIDER ALL OF ITS PROVISIONS BEFORE SIGNING
IT: IT INCLUDES A RELEASE OF KNOWN AND UNKNOWN CLAIMS. IF YOU WISH, YOU SHOULD TAKE ADVANTAGE OF
THE FULL CONSIDERATION PERIOD SET FORTH ABOVE AND CONSULT YOUR ATTORNEY.

     This Agreement constitutes the complete, final and exclusive embodiment of the entire
agreement between the Company and Wheeler with regard to the subject matter hereof. Wheeler is not
relying on any promise or representation, written or oral, which is not expressly stated herein.
This Agreement may only be modified by a written agreement signed by both Wheeler and a duly
authorized officer of the Company.

Understood and agreed:

	 	 	 	 	 
	 
	 	 	 	 
	/s/ Wesley P. Wheeler
 

Wesley P. Wheeler

	 	12/13/07

 

Date	 	 

	 	 	 	 	 
	Valeant Pharmaceuticals International

 	 	 
	By:  	/s/ Timothy C. Tyson
 	 	 

Date:
12/13/07 

5.

 

	 	 	 	 	 

EXHIBIT A

Separation Payment

     If Wheeler signs and returns the attached Separation and Release Agreement as provided
therein, the Company will make a lump sum payment to Wheeler, within ten (10) days after the
Effective Date, of three hundred thousand dollars ($300,000), subject to standard payroll
deductions and withholdings.

6.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]